TABLE 4.
Surveillance for acyclovir-resistant HSV in the immunocompromised population
| Variable tested | Results in reference:
|
||||
|---|---|---|---|---|---|
| 98 | 27 | 14 | 13 | Abstracta | |
| Prevalence of resistant HSV (%)b | 4.1 | 4.7 | 6.3 | 7.1 | 5.6 |
| No. of patients with resistant HSV/no. of patients tested | 3/74c | 7/148 | 6/95 | 14/196 | 12/216d |
| Period of surveillance | Not specified | Not specified | 1991-1993 | 1996-1999 | 1998-2000 |
| Location of survey | United States | United States | United Kingdom | France | North America |
| Reason for immunodeficiency | BMTe | BMT, HIV, organ transplant, malignancy, high-dose steroids, neonate | BMT, HIV, organ transplant, malignancy | BMT | HIV |
| Assay method | Dye uptake | Viral DNA inhibition | Plaque reduction assay | Dye uptake | Plaque reduction assay |
a
Gnann et al., Abstr. 38th Int. Conf. Dis. Soc. Am.
b
Acyclovir-resistant HSV. With the exception of reference 27 and Gnann et al., data are from acyclovir-treated patients only.
c
Acyclovir-resistant HSV was recovered from 1 of 52 patients during the initial treatment course and from 2 of 22 patients during treatment for second recurrences.
d
Number of acyclovir-resistant HSV isolates/number of isolates tested. Multiple isolates from some patients were tested.
e
BMT, bone marrow transplant recipient.